SUNLENCA 300 mg, film-coated tablet 5 tablets
Active ingredients: Lenacapavir, Lenacapavir sodium
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet5 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SUNLENCA 300 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC aluminium avec fermeture de sécurité enfant de 5 comprimé(s)
- Marketing authorisation holder
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 20 Dec 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
62721516CIP73025805CIP133400930258057Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉNACAPAVIRcomprimé | 300 mg · un comprimé | FT |
| LÉNACAPAVIR SODIQUEcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.